NCT01470716 2022-04-06
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
National Cancer Center, Korea
Phase 2 Unknown
Clinical Trials
5 trialsNCT03126799 2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2 Unknown
NCT01320501 2016-05-13
REALME
National Guard Health Affairs
Phase 4 Suspended
NCT00620269 2011-11-07
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
National Cancer Center, Korea
Phase 2 Unknown
NCT00268684 2006-02-28
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Tel-Aviv Sourasky Medical Center
Phase 3 Unknown